"'Remsima SC' Shows Improved Treatment Efficacy Compared to Infliximab IV"

Research Findings Presented at the European Rheumatology Society Meeting

Remsima SC.

[Asia Economy Reporter Lee Gwan-joo] At the European League Against Rheumatism (EULAR), new research results were announced on the 2nd showing that treatment with 'Remsima SC' (generic name infliximab) statistically significantly improved clinical indicators compared to the intravenous (IV) infliximab formulation.

EULAR is the world's largest conference attended by more than 15,000 rheumatology specialists and related experts worldwide, and this year it is being held both online and offline from the 1st to the 4th (local time) in Copenhagen, Denmark.

This study, conducted as a post-analysis of a global phase 3 clinical trial, analyzed whether Remsima SC showed numerically and statistically significant differences compared to infliximab IV in patients with rheumatoid arthritis (RA). A total of 343 patients receiving infliximab IV were randomly divided into two groups: 165 patients received 120 mg of Remsima SC biweekly at week 6, and 174 patients received 3 mg/kg IV every 8 weeks, with data analyzed at week 30. Additionally, at week 54, a comparative analysis was conducted between the IV patient group who switched to Remsima SC at week 30 and the group randomly assigned to Remsima SC at week 6.

The study results confirmed that at week 30, the Remsima SC patient group showed statistically significant differences and improved treatment efficacy in most clinical indicators, including lower disease activity (LDA) and remission rates, compared to the infliximab IV patient group. EULAR sets the treatment goal for RA therapies to achieve LDA and remission within six months (30 weeks) and recommends changing the treatment if these goals are not met. Given that the study results provide efficacy data consistent with EULAR guidelines, it is expected that the preference for prescribing Remsima SC among global healthcare professionals will increase.

Professor Arnaud Constantin, a rheumatology specialist at Paul Sabatier University and Purpan University Hospital in France, who led the study, stated, "For RA patients, effectively controlling the disease is crucial, so it is necessary to reconsider existing treatment methods when signs of reduced drug efficacy are detected." He added, "This study confirmed that patients switching to Remsima SC can manage their disease more effectively and improve their quality of life."

Choi Byung-seo, Head of Marketing at Celltrion Healthcare, said, "The study results demonstrated improved treatment efficacy of Remsima SC compared to infliximab IV in key clinical indicators." He continued, "Since the increased efficacy when switching from infliximab IV to Remsima SC was also confirmed, we are confident that trust in Remsima SC among healthcare professionals and patients will grow. We will actively promote the newly announced research results in the market and strive to expand Remsima SC prescriptions."

This content was produced with the assistance of AI translation services.